BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22343334)

  • 1. Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation.
    Macedo C; Walters JT; Orkis EA; Isse K; Elinoff BD; Fedorek SP; McMichael JM; Chalasani G; Randhawa P; Demetris AJ; Zeevi A; Tan H; Shapiro R; Landsittel D; Lakkis FG; Metes D
    Transplantation; 2012 Apr; 93(8):813-21. PubMed ID: 22343334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
    Kamburova EG; Koenen HJ; van den Hoogen MW; Baas MC; Joosten I; Hilbrands LB
    PLoS One; 2014; 9(11):e112658. PubMed ID: 25393622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.
    Trzonkowski P; Zilvetti M; Chapman S; Wieckiewicz J; Sutherland A; Friend P; Wood KJ
    Am J Transplant; 2008 Feb; 8(2):338-47. PubMed ID: 18211507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevation of CD4+ differentiated memory T cells is associated with acute cellular and antibody-mediated rejection after liver transplantation.
    Gerlach UA; Vogt K; Schlickeiser S; Meisel C; Streitz M; Kunkel D; Appelt C; Ahrlich S; Lachmann N; Neuhaus P; Pascher A; Sawitzki B
    Transplantation; 2013 Jun; 95(12):1512-20. PubMed ID: 23619734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation.
    Cherukuri A; Salama AD; Carter C; Smalle N; McCurtin R; Hewitt EW; Hernandez-Fuentes M; Clark B; Baker RJ
    Am J Transplant; 2012 Apr; 12(4):919-31. PubMed ID: 22390816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The balance between memory and regulatory cell populations in kidney transplant recipients with operational tolerance.
    Süsal C; Alvarez CM; Benning L; Daniel V; Zeier M; Schaier M; Morath C; Speer C
    Clin Exp Immunol; 2024 May; 216(3):318-330. PubMed ID: 38393856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.
    Xu H; Samy KP; Guasch A; Mead SI; Ghali A; Mehta A; Stempora L; Kirk AD
    Am J Transplant; 2016 Feb; 16(2):550-64. PubMed ID: 26436448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P; Zilvetti M; Friend P; Wood KJ
    Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection.
    Castro-Rojas CM; Godarova A; Shi T; Hummel SA; Shields A; Tremblay S; Alloway RR; Jordan MB; Woodle ES; Hildeman DA
    Transplantation; 2020 May; 104(5):1058-1069. PubMed ID: 31415033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
    Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
    Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of functionally distinct T-lymphocyte subsets in heart transplant recipients after induction therapy with anti-CD25 monoclonal antibodies.
    Lanio N; Sarmiento E; Gallego A; Navarro J; Palomo J; Fernandez-Yañez J; Ruiz M; Fernandez-Cruz E; Carbone J
    Transpl Immunol; 2013 Jun; 28(4):176-82. PubMed ID: 23611763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terminally Differentiated Effector Memory CD8
    Jacquemont L; Tilly G; Yap M; Doan-Ngoc TM; Danger R; Guérif P; Delbos F; Martinet B; Giral M; Foucher Y; Brouard S; Degauque N
    J Am Soc Nephrol; 2020 Apr; 31(4):876-891. PubMed ID: 32165419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
    Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
    Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
    Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
    Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppression Has Long-Lasting Effects on Circulating Follicular Regulatory T Cells in Kidney Transplant Recipients.
    Niu Q; Mendoza Rojas A; Dieterich M; Roelen DL; Clahsen-van Groningen MC; Wang L; van Gelder T; Hesselink DA; van Besouw NM; Baan CC
    Front Immunol; 2020; 11():1972. PubMed ID: 32983131
    [No Abstract]   [Full Text] [Related]  

  • 16. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial.
    Bösmüller C; Ollinger R; Sieb M; Weissenbacher A; Schneeberger S; Pratschke J; Margreiter R
    Ann Transplant; 2012 Dec; 17(4):45-51. PubMed ID: 23274323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical rejection and persistent immune regulation in kidney transplant patients.
    Hendrikx TK; Klepper M; Ijzermans J; Weimar W; Baan CC
    Transpl Immunol; 2009 Jul; 21(3):129-35. PubMed ID: 19398001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients.
    Kirsch BM; Haidinger M; Zeyda M; Böhmig GA; Tombinsky J; Mühlbacher F; Watschinger B; Hörl WH; Säemann MD
    Transpl Immunol; 2006 Nov; 16(3-4):254-7. PubMed ID: 17138063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H).
    Gallon L; Gagliardini E; Benigni A; Kaufman D; Waheed A; Noris M; Remuzzi G
    Clin J Am Soc Nephrol; 2006 May; 1(3):539-45. PubMed ID: 17699257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation.
    Uemura T; Ramprasad V; Matsushima K; Shike H; Valania T; Kwon O; Ghahramani N; Shah R; Farooq U; Khan A; Kadry Z
    Transplantation; 2011 Sep; 92(6):678-85. PubMed ID: 21841541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.